BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Drug Development

  It’s Full Speed Ahead for Many Alzheimer’s Players Following CMS Decision

  Following the decision to limit the coverage of Biogen’s controversial Alzheimer’s drug Aduhelm, the Alzheimer’s community is now waiting for other companies to deliver new therapies.

  April 11, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  Researchers Push for Intranasal Approach as COVID-19 Variants Persist

  Some researchers are pointing to the need for an intranasal approach to vaccination in order to block the viral particles from gaining a foothold in the body at the point of entry – the nose.

  April 11, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Biotech Bay

  Astellas-backed Turn Bio is Advancing Epigenetics for Long, Healthy Life Span

  Turn Bio’s platform is based on using mRNA technology to develop novel medicines to combat age-related diseases.

  April 11, 2022

   · 

  3 min read

   · 

  Hayley Shasteen
• 

  Drug Development

  Veru Soars as Oral Antiviral for COVID-19 Reduces Deaths by 55%

  Veru posted positive interim Phase III data from its late-stage study assessing oral antiviral sabizabulin in hospitalized COVID-19 patients. Here’s more about it.

  April 11, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  Cytovia is Empowering NK Cells and NK Engager Antibodies Against Cancer

  Cytovia could become the first company to use a combination of natural killer (NK) cells derived from induced pluripotent stem cell (iPSC) and NK engager antibodies to treat solid tumors.

  April 11, 2022

   · 

  4 min read

   · 

  Gail Dutton
• 

  Drug Development

  AACR: The Weekend Losers According to Wall Street

  Shares fell in several life sciences companies at the close of the market Friday on apparently lackluster early data from their respective research projects. We look into each one below:

  April 11, 2022

   · 

  4 min read

   · 

  Vanessa Doctor, RN
• 

  Business

  Pfizer’s Bourla Touts New CFO’s “True Insights” into Healthcare System

  Pfizer has found its replacement for longtime Chief Financial Officer Frank D’Amelio, who announced his retirement from the company five months ago.

  April 11, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Policy

  Rethinking Boosters and Personal Responsibility as Pandemic Enters New Phase

  The FDA is looking at revising the current vaccine strategy and emphasizing that individuals need to consider their own risk tolerance. For that and more, continue reading.

  April 11, 2022

   · 

  5 min read

   · 

  Mark Terry
• 

  RNA, tRNA, circRNA: Just Imagine the Therapeutic Possibilities!

  mRNA therapies are the future of treatments for many different conditions. Now, other types of RNA therapy are getting attention too, and it’s sparking exciting new developments.

  April 11, 2022

   · 

  3 min read

   · 

  Hannah Chudleigh
• 

  Drug Development

  AACR: Monday’s Stars Include Affimed, Hoth and Blueprint

  The American Association for Cancer Research (AACR) Annual Meeting is running from April 7-13 in New Orleans. Here’s a look at some of the preclinical and early-stage studies recently presented.

  April 11, 2022

   · 

  4 min read

   · 

  Mark Terry